Ambit Biosciences Stock Price, News & Analysis (NASDAQ:AMBI)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Ambit Biosciences (NASDAQ:AMBI)

Ambit Biosciences logoAmbit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.

Receive AMBI News and Ratings via Email

Sign-up to receive the latest news and ratings for AMBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Ambit Biosciences (NASDAQ:AMBI) Frequently Asked Questions

What is Ambit Biosciences' stock symbol?

Ambit Biosciences trades on the NASDAQ under the ticker symbol "AMBI."

How were Ambit Biosciences' earnings last quarter?

Ambit Biosciences Corp (NASDAQ:AMBI) posted its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.03. The biopharmaceutical company earned $0.03 million during the quarter, compared to analysts' expectations of $3.50 million. View Ambit Biosciences' Earnings History.

Who are some of Ambit Biosciences' key competitors?

How do I buy Ambit Biosciences stock?

Shares of Ambit Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Ambit Biosciences?

Ambit Biosciences' mailing address is 11080 Roselle St, SAN DIEGO, CA 92121-1233, United States. The biopharmaceutical company can be reached via phone at +1-858-3342100.

MarketBeat Community Rating for Ambit Biosciences (AMBI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  79
MarketBeat's community ratings are surveys of what our community members think about Ambit Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ambit Biosciences (NASDAQ:AMBI) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Ambit Biosciences (NASDAQ:AMBI) Earnings History and Estimates Chart

Earnings by Quarter for Ambit Biosciences (NASDAQ:AMBI)

Ambit Biosciences (NASDAQ AMBI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/12/2014Q2 2014($0.58)($0.68)$0.03 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.47)($0.50)$3.50 million$0.03 millionViewListenView Earnings Details
3/20/2014Q4 2013($0.47)($0.40)ViewN/AView Earnings Details
11/7/2013Q3 2013($0.14)($0.12)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.26)$0.27ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Ambit Biosciences (NASDAQ:AMBI) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Ambit Biosciences (NASDAQ:AMBI)

No dividend announcements for this company have been tracked by

Insider Trades

Ambit Biosciences (NASDAQ AMBI) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Ambit Biosciences (NASDAQ:AMBI)

Ambit Biosciences (NASDAQ AMBI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/24/2013Foresite Capital Management I,major shareholderBuy79,569$6.93$551,413.17View SEC Filing  
5/23/2013Orbimed Advisors LlcMajor ShareholderBuy33,800$6.91$233,558.00View SEC Filing  
5/21/2013David P BonitaDirectorBuy680,471$7.97$5,423,353.87View SEC Filing  
(Data available from 1/1/2013 forward)


Ambit Biosciences (NASDAQ AMBI) News Headlines


SEC Filings

Ambit Biosciences (NASDAQ:AMBI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Ambit Biosciences (NASDAQ:AMBI) Income Statement, Balance Sheet and Cash Flow Statement


Ambit Biosciences (NASDAQ AMBI) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.